Rapid Development of
for Complex Antibodies
High Yield, Stable Cell Lines
2 chains BsAb
3 chains BsAb
4 chains BsAb
Nanobody
mAb
BiTE
AlfaCell is a Cell Line Development (CLD) platform that delivers clonal cell lines ready for Research Cell Bank (RCB) in ~6 weeks (project dependent). It combines fluorescence‑guided selection with site‑specific integration (SSI) to insert your gene(s) into pre‑characterized genomic hot spots designed for stable, high‑titer expression and robust product quality for complex formats.
RCB‑ready high‑yield, stable cell lines for complex antibodies — in 6 weeks:
High yield clone
Titers up to 20 g/L including difficult-to-express proteins
High correct pairing rate
>93% for BsAbs and other complex molecules
From sequence to RCB in 6 weeks
Clone selection can be aligned with parallel assay work (e.g., early developability/tox‑enabling plans)
AlfaCell Platform is designed to speed up the most optimal clone selection
AlfaCell platform reduces screening burden and improves predictability by combining targeted gene integration with visual enrichment. The result is faster identification of clones that meet productivity and stability requirements, with format‑relevant quality checks earlier in the workflow.
AI-Selected “Hot Spot” for Gene Integration
Over 100 000 000 cells were analyzed, correlating cell morphology with high protein synthesis to identify a “hot spot” and create a “super host cell line” with high yield titer of inserted gene.
Site Specific Integration Technology
Targeted insertion into pre‑selected stable genomic sites reduces positional effects and variability, supporting more predictable expression and clone stability
Proprietary Vector System
AlfaCell platform supports balanced expression for multi‑chain molecules and improves the probability of correct assembly/pairing of complex molecules, reducing mismatch‑driven clone cycling.
Deliverables: You receive RCB‑ready lead clone, and a clone data package aligned to your program (productivity, stability, and format‑relevant quality indicators). Methods and acceptance criteria can be aligned to your internal CMC standards or CDMO of your choice.
From 6+ Months to 1.5 Months: A Drastic Acceleration of the Development Timeline
The AlfaCell® platform delivers a stable, high-yield Research Cell Bank (RCB) in just 1.5 months.
Traditional CLD
Transfection
Blind Screening
(100+ plates)
Expansion
3-month Stability Study
6+
months
AlfaCell®
1.5
months
Transfection
Targeted Screening
(one 96-well plate)
Expansion
RCB
Stability evaluation not needed due to the
pre-validated site.
Demonstrated Outcomes
Consistent performance across a diverse range of complex therapeutic
molecules.
RCB: as Soon as 6 Weeks
Bispecific (BsAb)
8.3 g/L
88% Correct Pairing
High-yield expression with demonstrated chain pairing accuracy for complex bispecific formats.
Within 1.5 Months
Monoclonal (mAb)
19.5 g/L
Outstanding productivity for standard mAb
programs.
Within 2.5 Months
Nano BsAb
15.6 g/L
High performance in next-gen nanoformats.
Within 3 Months
Support Earlier Downstream Decisions and Scale-Up Planning
Traceable project documentation (cell line history, key characterization outputs, and RCB‑supporting records) can be aligned to your internal QA expectations.
Regulatory & IP
Regulatory SuPPORT
AlfaCel’sl cell lines have supported IND-enabling programs and submissions
Robust IP Portfolio
FTO cleared for US and China, IP/FTO: 60+ patents filed globally (31 granted);
MANAGEMENT SYSTEM
ISO 9001:2015 Quality Management System
See How AlfaCell Can Transform Your CLD Timeline - Speak with an Expert
© 2026 Great Bay Bio. All rights reserved. Precision CLD Platform.
Rapid Development of
for Complex Antibodies
High Yield, Stable Cell Lines
BiTE
4 chains BsAb
Nanobody
mAb
AlfaCell is a Cell Line Development (CLD) platform that delivers clonal cell lines ready for Research Cell Bank (RCB) in ~6 weeks (project dependent). It combines fluorescence‑guided selection with site‑specific integration (SSI) to insert your gene(s) into pre‑characterized genomic hot spots designed for stable, high‑titer expression and robust product quality for complex formats.
RCB‑ready high‑yield, stable cell lines for complex antibodies — in 6 weeks:
High yield clone
Titers up to 20 g/L including difficult-to-express proteins
High correct pairing rate
>93% for BsAbs and other complex molecules
From sequence to RCB in 6 weeks
Clone selection can be aligned with parallel assay work (e.g., early developability/tox‑enabling plans)
2 chains BsAb
3 chains BsAb
AlfaCell Platform is designed to speed up the most optimal clone selection
AlfaCell platform reduces screening burden and improves predictability by combining targeted gene integration with visual enrichment. The result is faster identification of clones that meet productivity and stability requirements, with format‑relevant quality checks earlier in the workflow.
AI-Selected “Hot Spot” for Gene Integration
Over 100 000 000 cells were analyzed, correlating cell morphology with high protein synthesis to identify a “hot spot” and create a “super host cell line” with high yield titer of inserted gene.
Site Specific Integration Technology
Targeted insertion into pre‑selected stable genomic sites reduces positional effects and variability, supporting more predictable expression and clone stability
Proprietary Vector System
AlfaCell platform supports balanced expression for multi‑chain molecules and improves the probability of correct assembly/pairing of complex molecules, reducing mismatch‑driven clone cycling.
Deliverables: You receive RCB‑ready lead clone, and a clone data package aligned to your program (productivity, stability, and format‑relevant quality indicators). Methods and acceptance criteria can be aligned to your internal CMC standards or CDMO of your choice.
Demonstrated Outcomes
Consistent performance across a diverse range of complex therapeutic
molecules.
RCB: as Soon as 6 Weeks
Monoclonal (mAb)
19.5 g/L
Outstanding productivity for standard mAb
programs.
Within 2.5 Months
Nano BsAb
15.6 g/L
High performance in next-gen nanoformats.
Within 3 Months
Bispecific (BsAb)
8.3 g/L
88% Correct Pairing
High-yield expression with demonstrated chain pairing accuracy for complex bispecific formats.
Within 1.5 Months
Support Earlier Downstream Decisions and Scale-Up Planning
Traceable project documentation (cell line history, key characterization outputs, and RCB‑supporting records) can be aligned to your internal QA expectations.
Regulatory & IP
Regulatory SuPPORT
AlfaCel’sl cell lines have supported IND-enabling programs and submissions
Robust IP Portfolio
FTO cleared for US and China, IP/FTO: 60+ patents filed globally (31 granted);
MANAGEMENT SYSTEM
ISO 9001:2015 Quality Management System
Support Earlier Downstream Decisions and Scale-Up Planning
Traceable project documentation (cell line history, key characterization outputs, and RCB‑supporting records) can be aligned to your internal QA expectations.
Regulatory & IP
Regulatory SuPPORT
AlfaCel’sl cell lines have supported IND-enabling programs and submissions
Robust IP Portfolio
FTO cleared for US and China, IP/FTO: 60+ patents filed globally (31 granted);
MANAGEMENT SYSTEM
ISO 9001:2015 Quality Management System
See How AlfaCell Can Transform Your CLD Timeline - Speak with an Expert
Support
Contact Us
Privacy Policy
Terms of Service
© 2026 Great Bay Bio. All rights reserved. Precision CLD Platform.
From 6+ Months to 1.5 Months: A Drastic
Acceleration of the Development Timeline
The AlfaCell® platform delivers a stable, high-yield Research Cell Bank (RCB)
in just 1.5 months.
Traditional CLD
Transfection
Blind
Screening
(100+ plates)
Expansion
3-month Stability
Study
6+
months
AlfaCell®
Transfection
Targeted
Screening
(one 96-well plate)
Expansion
RCB
Stability evaluation not needed due to the
pre-validated site.
1.5
months
Rapid Development of
for Complex Antibodies
High Yield, Stable Cell Lines
AlfaCell is a Cell Line Development (CLD) platform that delivers clonal cell lines ready for Research Cell Bank (RCB) in ~6 weeks (project dependent). It combines fluorescence‑guided selection with site‑specific integration (SSI) to insert your gene(s) into pre‑characterized genomic hot spots designed for stable, high‑titer expression and robust product quality for complex formats.
High yield clone
Titers up to 20 g/L including difficult-to-express proteins
High correct pairing rate
>93% for BsAbs and other complex molecules
From sequence to RCB in 6 weeks
Clone selection can be aligned with parallel assay work (e.g., early developability/tox‑enabling plans)
RCB‑ready high‑yield, stable cell lines for complex antibodies — in 6 weeks:
2 chains BsAb
3 chains BsAb
4 chains BsAb
Nanobody
mAb
BiTE
AlfaCell Platform is designed to speed up the most optimal clone selection
AlfaCell platform reduces screening burden and improves predictability by combining targeted gene integration with visual enrichment. The result is faster identification of clones that meet productivity and stability requirements, with format‑relevant quality checks earlier in the workflow.
AI-Selected “Hot Spot” for Gene Integration
Over 100 000 000 cells were analyzed, correlating cell morphology with high protein synthesis to identify a “hot spot” and create a “super host cell line” with high yield titer of inserted gene.
Site Specific Integration Technology
Targeted insertion into pre‑selected stable genomic sites reduces positional effects and variability, supporting more predictable expression and clone stability
Proprietary Vector System
AlfaCell platform supports balanced expression for multi‑chain molecules and improves the probability of correct assembly/pairing of complex molecules, reducing mismatch‑driven clone cycling.
Deliverables: You receive RCB‑ready lead clone, and a clone data package aligned to your program (productivity, stability, and format‑relevant quality indicators). Methods and acceptance criteria can be aligned to your internal CMC standards or CDMO of your choice.
Demonstrated Outcomes
Consistent performance across a diverse range of complex therapeutic
molecules.
RCB: as Soon as 6 Weeks
Bispecific (BsAb)
8.3 g/L
88% Correct Pairing
High-yield expression with demonstrated chain pairing accuracy for complex bispecific formats.
Within 1.5 Months
Monoclonal (mAb)
19.5 g/L
Outstanding productivity for standard mAb
programs.
Within 2.5 Months
Nano BsAb
15.6 g/L
High performance in next-gen nanoformats.
Within 3 Months
Support Earlier Downstream Decisions and Scale-Up Planning
Traceable project documentation (cell line history, key characterization outputs, and RCB‑supporting records) can be aligned to your internal QA expectations.
Regulatory & IP
Regulatory SuPPORT
AlfaCel’sl cell lines have supported IND-enabling programs and submissions
Robust IP Portfolio
FTO cleared for US and China, IP/FTO: 60+ patents filed globally (31 granted);
MANAGEMENT SYSTEM
ISO 9001:2015 Quality Management System
Support Earlier Downstream Decisions and Scale-Up Planning
Traceable project documentation (cell line history, key characterization outputs, and RCB‑supporting records) can be aligned to your internal QA expectations.
Regulatory & IP
Regulatory SuPPORT
AlfaCel’sl cell lines have supported IND-enabling programs and submissions
Robust IP Portfolio
FTO cleared for US and China, IP/FTO: 60+ patents filed globally (31 granted);
MANAGEMENT SYSTEM
ISO 9001:2015 Quality Management System
See How AlfaCell Can Transform Your CLD Timeline - Speak with an Expert
© 2026 Great Bay Bio. All rights reserved. Precision CLD Platform.
From 6+ Months to 1.5 Months: A Drastic
Acceleration of the Development Timeline
The AlfaCell® platform delivers a stable, high-yield Research Cell Bank (RCB)
in just 1.5 months.
Traditional CLD
Transfection
Blind
Screening
(100+ plates)
Expansion
3-month Stability
Study
6+
months
AlfaCell®
Transfection
Targeted
Screening
(one 96-well plate)
Expansion
RCB
Stability evaluation not needed due to the
pre-validated site.
1.5
months